Poster Abstracts
Grand Hall CD (Manchester Grand Hyatt)
Safety and Efficacy of Non-Myeloablative (NMA) Melphalan-Based Conditioning for Haploidentical Allogeenic Stem Cell Transplantation (HaploSCT) in Patients with Advanced Lymphoma
Jonathan E Brammer, MD, The University of Texas MD Anderson Cancer Center;
Issa F. Khouri, MD, The University of Texas MD Anderson Cancer Center;
Sameh Gaballa, MD, The University of Texas MD Anderson Cancer Center;
Celina Ledesma, BS, University of Texas, MD Anderson Cancer Center;
Paolo Anderlini, MD, UT MD Anderson Cancer Center;
Borje S. Andersson, MD, PhD, The University of Texas MD Anderson Cancer Center;
Uday R. Popat, MD, UT MD Anderson Cancer Center;
Qaiser Bashir, MD, The University of Texas MD Anderson Cancer Center;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Stefan O. Ciurea, MD, The University of Texas MD Anderson Cancer Center
Cyclophosphamide Is an Effective and Well-Tolerated Maintenance Therapy in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Michael Byrne, MD, Helen Diller Comprehensive Cancer Center, University of California;
Yunfeng Dai, M.S., University of Florida;
Jayan Nair, MD, Sanford Health;
Myron Chang, PhD, University of Florida;
Jan S. Moreb, MD, University of Florida
Reduced Intensity Allogeneic Stem Cell Transplantation Followed By Adoptive Cellular Immunotherapy with Donor Derived LMP Specific-CTLs in Patients with EBV Positive Refractory or Recurrent Hodgkin Lymphoma: A Lymphoma Cell Therapy Consortium (LCTC) Trial
Jessica Hochberg, MD, New York Medical College;
Renuka P Miller, PhD, Children’s National Medical Center;
Patrick J Hanley, PhD, Children's National Medical Center;
Sarah McCormack, Children's National Medical Center;
Lauren Harrison, RN, New York Medical College;
Olga Militano, PharmD, New York Medical College;
Phyllis Brand, RN, MPH, New York Medical College;
Catherine M. Bollard, MD, Children's National Medical Center;
Mitchell S. Cairo, MD, New York Medical College
Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Hodgkin's Disease
Doris Hovgaard, MD, Rigshospitalet, Copenhagen University Hospital;
Henrik Sengeløv, MD, DMSc, Rigshospitalet, Copenhagen University Hospital;
Lars Vindeløv, MD, DMSc, Rigshospitalet, Copenhagen University Hospital
Administration of Mogamulizumab before Allogeneic Hematopoietic Cell Transplantation Against ATLL Might Increase Risks of Acute Gvhd and Non-Relapse Mortality
Yoshitaka Inoue, MD, National Cancer Center Hospital;
Shigeo Fuji, MD, National Cancer Center Hospital;
Ryuji Tanosaki, MD, National Cancer Center Hospital;
Reiko Ito, MD, National Cancer Center Hospital;
Takashi Tanaka, MD, National Cancer Center Hospital;
Yoshihiro Inamoto, MD PhD, National Cancer Center Hospital;
Keiji Okinaka, MD, National Cancer Center Hospital;
Saiko Kurosawa, MD, National Cancer Center Hospital;
Sung-Won Kim, MD, National Cancer Center Hospital;
Takuya Yamashita, MD, National Cancer Center Hospital;
Takahiro Fukuda, MD, PhD, National Cancer Center Hospital
The Histone Deacetylase Inhibitor SAHA Sensitizes Lymphoma Cells to Combination of Cladribine and Gemcitabine with DNA Alkylating Agent Busulfan
Jie Ji, MD, UT MD Anderson Cancer Center;
Ben C. Valdez, PhD, UT M.D. Anderson Cancer Center;
Yang Li, MS, UT MD Anderson Cancer Center;
Yan Liu, UT MD Anderson Cancer Center;
Esmeralda C Teo, MD, UT M.D. Anderson Cancer Center;
Yago L. Nieto, MD, PhD, UT MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Borje S. Andersson, MD, PhD, UT M.D. Anderson Cancer Center
A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, yttrium-90 ibritumomab tiuxetan) for Patients with Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma
Limin Gao, MD, MPH, PhD, Tufts Medical Center;
Kellie A Sprague, MD, Tufts Medical Center;
Nayer Nikpoor, MD, Tufts Medical Center;
Hans G Klingemann, MD, PhD, Tufts Medical Center;
Kenneth B. Miller, MD, Tufts Medical Center;
Raymond Comenzo, MD, Tufts Medical Center;
Andreas K Klein, MD, Tufts Medical Center
Outcomes of Second Autologous Stem Cell Transplant in Patients with Renal Dysfunction
Lakshminarayanan Nandagopal, MD, karmanos cancer intitute;
Christine Ye, MD, Karmanos cancer intitute;
Muneer H. Abidi, MD, Karmanos Cancer Institute/ Wayne State University;
Lois Jeanne Ayash, MD, Karmanos Cancer Institute/ Wayne State University;
Richard Manasa, Karmanos Cancer Institute - Wayne State Univ;
Lawrence Lum, MD, DSc, Karmanos Cancer Institute;
Joseph Uberti, MD, Karmanos Cancer Institute/ Wayne State University;
Voravit Ratanatharathorn, MD, Karmanos Cancer Institute/ Wayne State University;
Jeffrey Zonder, MD, Karmanos cancer intitute;
Divaya Bhutani, MD, Karmanos Cancer Institute;
Abhinav Deol, MD, Karmanos Cancer Institute/ Wayne State University
Influence of Race on Outcomes in Multiple Myeloma Patients with Renal Dysfunction Undergoing Autologous Stem Cell Transplant
Lakshminarayanan Nandagopal, MD, karmanos cancer intitute;
Christine Ye, MD, Karmanos cancer intitute;
Marie Ventimiglia, Wayne State University Hospital;
Muneer H. Abidi, MD, Karmanos Cancer Institute/ Wayne State University;
Lois Jeanne Ayash, MD, Karmanos Cancer Institute/ Wayne State University;
Jeffrey Zonder, MD, Karmanos cancer intitute;
Lawrence Lum, MD, DSc, Karmanos Cancer Institute;
Joseph Uberti, MD, Karmanos Cancer Institute/ Wayne State University;
Voravit Ratanatharathorn, MD, Karmanos Cancer Institute/ Wayne State University;
Divaya Bhutani, MD, Karmanos Cancer Institute;
Abhinav Deol, MD, Karmanos Cancer Institute/ Wayne State University
Adequate and Predictable Stem Cell (SC) Collection and Low Incidence of Neutropenic Fever (NF) with Cyclophosphamide (C) and G-CSF Mobilization in Multiple Myeloma (MM) : A Single Center Analysis
Bhavisha Patel, MD, UMass Memorial Medical Center;
Zheng Zhou, University of Massachusetts;
Juliet Appiah, MD, UMass Memorial Medical Center;
Glen Raffel, MD, PhD, UMass Medical Center;
Zankar Desai, University of Massachusetts Medical Center;
Jayde Bednarik, PharmD, UMass Memorial Health Care;
Tzafra Tessier, PA, UMass Memorial Medical Center;
Jenna L'Heureux, NP, UMass Memorial Medical Center;
Jan Cerny, MD, PhD, FACP, University of Massachusetts;
Muthalagu Ramanathan, MD, University of Massachusetts;
Rajneesh Nath, MD, UMass Memorial Medical Center
Mantle Cell Lymphoma: Outcomes after Hematopoietic Stem Cell Transplantation
Priyanka Pathak, MD, MPH, Thomas Jefferson University;
S Vikas Kumar, MD, Thomas Jefferson University;
Onder Alpdogan, MD, Thomas Jefferson University;
Matthew Carabasi, MD, Thomas Jefferson University;
Neal Flomenberg, MD, Thomas Jefferson University;
Dolores Grosso, DNP, Thomas Jefferson University;
Ubaldo Martinez-Outschoorn, MD, Thomas Jefferson University;
John Wagner, MD, Thomas Jefferson University;
Mark Weiss, MD, Thomas Jefferson University;
Barbara Pro, MD, Thomas Jefferson University;
Joanne Filicko-O'Hara, MD, Thomas Jefferson University
Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation
Koji Sasaki, MD, The University of Texas MD Anderson Cancer Center;
Rima Saliba, PhD, The University of Texas MD Anderson Cancer Center;
Gary Lu, MD, The University of Texas MD Anderson Cancer Center;
Nina Shah, MD, The University of Texas MD Anderson Cancer Center;
Qaiser Bashir, MD, The University of Texas MD Anderson Cancer Center;
Krina Patel, MD, The University of Texas MD Anderson Cancer Center;
Fabian Bock, MD, The University of Texas MD Anderson Cancer Center;
Simrit Parmar, MD, The University of Texas MD Anderson Cancer Center;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center;
Uday R. Popat, MD, UT MD Anderson Cancer Center;
Ruby Delgado, The University of Texas MD Anderson Cancer Center;
Gabriela Rondon, MD, The University of Texas MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Muzaffar H. Qazilbash, MD, The University of Texas MD Anderson Cancer Center
Gain of Chromosome 1q Portends Worse Prognosis in Multiple Myeloma Patients with Treated with Novel Agent Based Induction Regimens Even after Autologous Transplantation
Gunjan L. Shah, MD MS, Memorial Sloan-Kettering Cancer Center;
Chrystal Landry, MD, NY Presbyterian Hospital - Weill Cornell Medical College;
Dory Londono, Memorial Sloan-Kettering Cancer Center;
Sean Devlin, PhD, Memorial Sloan Kettering Cancer Center;
Satyajit Kosuri, MD, Memorial Sloan-Kettering Cancer Center;
Alexander M Lesokhin, MD, Weill Cornell Medical College;
Nikoletta Lendvai, MD PhD, Weill Cornell Medical College;
Hani Hassoun, MD, Memorial Sloan-Kettering Cancer Center;
David J. Chung, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Guenther Koehne, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Suresh Jhanwar, PhD, Memorial Sloan-Kettering Cancer Center;
Ola Landgren, MD PhD, Weill Cornell Medical College;
Heather Landau, MD, Memorial Sloan-Kettering Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center
The Graft-Versus-Lymphoma Effect in Diffuse Large B-Cell Lymphoma
Christina A.M. Smith, University of Michigan;
Tracey L. Churay, University of Michigan;
Holly A. Justman, University of Michigan;
Jessica K. Yu, University of Michigan;
Attaphol Pawarode, MD, University of Michigan;
David Hanauer, M.S., M.D., University of Michigan;
John Magenau, M.D., University of Michigan;
Steven C. Goldstein, MD, University of Pennsylvania;
Mary Mansour Riwes, DO, University of Michigan;
Brian Parkin, MD, University of Michigan;
John Levine, MD, MS, University of Michigan;
Daniel R. Couriel, MD, MS, University of Michigan
![[Visit Client Website]](images/banner.gif)